Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 6/2015

01.06.2015 | Hypertension and Obesity (E Reisin, Section Editor)

The Kidney in Obesity

verfasst von: Josep Redon, Empar Lurbe

Erschienen in: Current Hypertension Reports | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Body mass index has been found to be the second most important contributor to relative risk for developing end state renal disease (ESRD), after proteinuria. The impact of obesity on the kidney includes a wide spectrum, from characteristic pathologic lesions to increment in urinary albumin excretion (UAE) and proteinuria/or decrease in glomerular filtration rate (GFR). The cause of renal disease associated to obesity is not well understood, but two relevant elements emerge. The first is the presence of obesity-related glomerulopathy, and the second is the fat deposit in the kidney with impact on renal haemodynamics and intrarenal regulation. The mechanisms linking obesity and renal damage are complex and include haemodynamic changes, inflammation, oxidative stress, apoptosis, and finally renal scarring. The protection of kidney damage needs to combine weight reduction with the proper control of the cardiometabolic risk factors associated, hypertension, metabolic syndrome, diabetes and dyslipidaemia. The search for specific treatments merits future research.
Literatur
1.•
Prospective Studies Collaboration. Body-mass index and cause specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–96. The relevance of BMI in mortality is collected based in a large number of prospective studies. PubMedCentralCrossRef
2.
Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9 · 1 million participants. Lancet. 2011;377:557–67.CrossRefPubMed
3.
Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg Sweden. BMJ. 1984;289:1257–61.PubMedCentralCrossRefPubMed
4.
Ducimetière P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris prospective study. Int J Obes. 1986;10:229–40.PubMed
5.
Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older men. Am J Epidemiol. 1995;141:1117–27.PubMed
6.
Rexrode KM, Hennekens CH, Willet WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277:1539–45.CrossRefPubMed
7.
Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Am J Epidemiol. 1998;148:1187–94.CrossRefPubMed
8.
Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA project. Int J Obes. 1999;23:116–22.CrossRef
9.
Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP, et al. Associations of general and abdominal obesity with multiple health outcomes in older women. The Iowa women’s health study. Arch Intern Med. 2000;60:2117–28.CrossRef
10.
Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J. 2002;23:705–13.CrossRef
11.
Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, et al. Body mass index and the risk of stroke in men. Arch Intern Med. 2002;162:2557–62.CrossRefPubMed
12.
Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case control study. Lancet. 2005;366:1640–9.CrossRefPubMed
13.
Gelber RP, Gaziano JM, Orav EJ, Manson JE, Buring JE, Kurth T. Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol. 2008;52:605–15.PubMedCentralCrossRefPubMed
14.
Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008;26:1891–900.CrossRefPubMed
15.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. N Engl J Med. 2004;351:1296–306.CrossRefPubMed
16.
Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef
17.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.CrossRefPubMed
18.
Aitken GR, Roderick PJ, Fraser S, Mindell JS, O'Donoghue D, Day J, et al. Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010. BMJ Open. 2014;4, e005480.PubMedCentralCrossRefPubMed
19.
Komura H, Nomura I, Kitamura K, Kuwasako K, Kato J. Gender difference in relationship between body mass index and development of chronic kidney disease. BMC Res Notes. 2013;6:463.PubMedCentralCrossRefPubMed
20.
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.CrossRefPubMed
21.
Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479–87.PubMed
22.
Mohsen A, Brown R, Hoefield R, Kalra PA, O'Donoghue D, Middleton R, et al. Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus. J Nephrol. 2012;25:384–93.CrossRefPubMed
23.
Brown RN, Mohsen A, Green D, Hoefield RA, Summers LK, Middleton RJ, et al. Body mass index has no effect on rate of progression of chronic kidney disease in non-diabetic subjects. Nephrol Dial Transplant. 2012;27:2776–80.CrossRefPubMed
24.
França AK, Dos Santos AM, Salgado JV, Hortegal EV, da Silva AA, Salgado FN. Estimated visceral adipose tissue, but not body mass index, is associated with reductions in glomerular filtration rate based on cystatin C in the early stages of chronic kidney disease. Int J Nephrol. 2014;2014:574267.PubMedCentralCrossRefPubMed
25.
Odagiri K, Mizuta I, Yamamoto M, Miyazaki Y, Watanabe H, Uehara A. Waist to height ratio is an independent predictor for the incidence of chronic kidney disease. PLoS One. 2014;9:e88873.PubMedCentralCrossRefPubMed
26.
Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.CrossRefPubMed
27.••
Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–73. Systematic review of the association between MetS, its components, and development of microalbuminuria or proteinuria and CKD in 30146 subjects. The study demonstrated the impact of metabolic síndrome in the development of microalbuminuria, proteinuria and CKD. PubMedCentralCrossRefPubMed
28.
Song H, Wang X, Cai Q, Ding W, Huang S, Zhuo L. Association of metabolic syndrome with decreased glomerular filtration rate among 75,468 Chinese adults: a cross-sectional study. PLoS One. 2014;9, e113450.PubMedCentralCrossRefPubMed
29.
Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;7:421–35.PubMedCentralCrossRefPubMed
30.
Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169:342–50.PubMedCentralCrossRefPubMed
31.
Vupputuri S, Fox CS, Coresh J, Woodward M, Muntner P. Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index. Am J Kidney Dis. 2009;53:993–1001.PubMedCentralCrossRefPubMed
32.
Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.CrossRefPubMed
33.
Serra A, Romero R, Lopez D, Navarro M, Esteve A, Perez N, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int. 2008;73:947–55.CrossRefPubMed
34.••
de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2:417–26. The study collects the evidence of the ectopic lipid accumulation in the kidney and its relationship with obesity related renal disease, including hemodynamic and structural changes. CrossRefPubMed
35.
36.
Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53:751–59.PubMedCentralCrossRefPubMed
37.
Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212–22.CrossRefPubMed
38.
Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, et al. Podocyte injury damages other podocytes. J Am Soc Nephrol. 2011;22:1275–85.PubMedCentralCrossRefPubMed
39.
Wagner R, Machann J, Lehmann R, Rittig K, Schick F, Lenhart J, et al. Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Diabetologia. 2012;55:2054–8.CrossRefPubMed
40.••
Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: the Framingham heart study. Hypertension. 2011;58:784–90. In participants from the Framingham Heart Study underwent quantification of renal sinus fat area using computed tomography. With a prevalence of fatty kidney of 30 %, it was a risk for having hypertension independent of potential counfounding factors. Renal sinus fat may play a role in blood pressure regulation and chronic kidney disease. PubMedCentralCrossRefPubMed
41.
Stefan N, Artunc F, Heyne N, Machann J, Schleicher ED, Häring HU. Obesity and renal disease: not all fat is created equal and not all obesity is harmful to the kidneys. Nephrol Dial Transplant. 2014. Apr 20.
42.•
Felizardo RJ, da Silva MB, Aguiar CF, Câmara NO. Obesity in kidney disease: a heavyweight opponent. World J Nephrol. 2014;3:50–63. The review discussed the consequences of obesity in the context of renal injury. PubMedCentralCrossRefPubMed
43.
Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension. 1995;26:610–5.CrossRefPubMed
44.
Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 2007;71:260–5.CrossRefPubMed
45.
Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14:1480–6.CrossRefPubMed
46.
Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension. 2005;46:1316–20.CrossRefPubMed
47.
De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant. 2013;28:29–36.CrossRefPubMed
48.
Chen S, Chen Y, Liu X, Li M, Wu B, Li Y, et al. Association of insulin resistance with chronic kidney disease in non-diabetic subjects with normal weight. PLoS One. 2013;8:e74058.PubMedCentralCrossRefPubMed
49.
Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J. 2011;75:2739–48.CrossRefPubMed
50.
Nolan E, O'Meara YM, Godson C. Lipid mediators of inflammation in obesity-related glomerulopathy. Nephrol Dial Transplant. 2013;28(4):iv22–9.PubMed
51.
Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39:1–11.CrossRefPubMed
52.
Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33:54–65.CrossRefPubMed
53.
Rutkowski JM, Wang ZV, Park AS, Zhang J, Zhang D, Hu MC, et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol. 2013;24:268–82.PubMedCentralCrossRefPubMed
54.
Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Bárány P, Lönnqvist F, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69:596–604.CrossRefPubMed
55.
Kang YS, Song HK, Lee MH, Ko GJ, Han JY, Han SY, et al. Visfatin is upregulated in type-2 dia- betic rats and targets renal cells. Kidney Int. 2010;78:170–81.CrossRefPubMed
56.
Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21:406–12.CrossRefPubMed
57.
Nishiyama A, Abe Y. Molecular mechanisms and therapeu- tic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci. 2006;100:9–16.CrossRefPubMed
58.
Sharma K. Obesity, oxidative stress, and fibrosis in chronic kidney disease. Kidney Int Suppl. 2014;4(4):113–7.CrossRef
59.••
Declèves AE, Zolkipli Z, Satriano J, Wang L, Nakayama T, Rogac M, et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 2014;85:611–23. The role of AMP-activated protein kinase, a critical pathway in regulating renal lipid accumulation is reviewed. PubMedCentralCrossRefPubMed
60.
Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123:4888–99.PubMedCentralCrossRefPubMed
61.
Chen B, Yang D, Chen Y, Xu W, Ye B, Ni Z. The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. Clin Chim Acta. 2010;411:705–9.CrossRefPubMed
62.
Thoenes M, Reil JC, Khan BV, Bramlage P, Volpe M, Kirch W, et al. Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag. 2009;55:577–85.
63.
Chandie Shaw PK, Berger SP, Mallat M, Frölich M, Dekker FW, Rabelink TJ. Central obesity is an independent risk factor for albuminuria in nondiabetic south Asian subjects. Diabetes Care. 2007;30:1840–4.CrossRefPubMed
64.
Du N, Peng H, Chao X, Zhang Q, Tian H, Li H. Interaction of obesity and central obesity on elevated urinary albumin-to-creatinine ratio. PLoS One. 2014;9:e98926.PubMedCentralCrossRefPubMed
65.
Goknar N, Oktem F, Ozgen IT, Torun E, Kuçukkoc M, Demir AD, et al. Determination of early urinary renal injury markers in obese children. Pediatr Nephrol. 2015;30:139–44.CrossRefPubMed
66.
Xiao N, Jenkins TM, Nehus E, Inge TH, Michalsky MP, Harmon CM, et al. Kidney function in severely obese adolescents undergoing bariatric surgery. Obesity. 2014;22:2319–25.CrossRefPubMed
67.
Lurbe E, Torro MI, Alvarez J, Aguilar F, Fernandez-Formoso JA, Redon J. Prevalence and factors related to urinary albumin excretion in obese youths. J Hypertens. 2013;31:2230–6.CrossRefPubMed
68.
Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr. 2001;138:481–5.CrossRefPubMed
69.
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community- based population. JAMA. 2004;291:844–50.CrossRefPubMed
70.
Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyrén O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.CrossRefPubMed
71.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRefPubMed
72.
Franceschini N, Gouskova NA, Reiner AP, Bostom A, Howard BV, Pettinger M, Umans JG, Brookhart MA, Winkelmayer WC, Eaton CB, Heiss G, Fine JP. Adiposity patterns and the risk for ESRD in postmenopausal women. Clin J Am Soc Nephrol. 2014; Dec 1.
73.
Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, Yamazaki M, Oda Y, Hasegawa G, Toda H, Nakamura N, Fukui M. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015; Jan 29.
74.
Song YM, Sung J, Lee K. Longitudinal relationships of metabolic syndrome and obesity with kidney function: healthy twin study. Clin Exp Nephrol. 2015; Jan 30.
75.
Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, Warnock DG, Judd SE, Gutiérrez OM. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2014; Dec 17.
76.
Chen S, Zhou S, Wu B, Zhao Y, Liu X, Liang Y, et al. Association between metabolically unhealthy overweight/obesity and chronic kidney disease: the role of inflammation. Diabetes Metab. 2014;40:423–30.CrossRefPubMed
77.
Hoogeveen EK, Halbesma N, Rothman KJ, Stijnen T, van Dijk S, Dekker FW, et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol. 2012;7:280–8.PubMedCentralCrossRefPubMed
78.
Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, Mallat MJ, Borm G, et al. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011;91:869–74.CrossRefPubMed
79.
Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.CrossRefPubMed
80.
Sharma D, Hawkins M, Abramowitz MK. Association of sarcopenia with eGFR and misclassification of obesity in adults with CKD in the United States. Clin J Am Soc Nephrol. 2014;9:2079–88.CrossRefPubMed
81.
Hanly PJ, Ahmed SB. Sleep apnea and the kidney: is sleep apnea a risk factor for chronic kidney disease? Chest. 2014;146:1114–22.CrossRefPubMed
82.
Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.PubMedCentralCrossRefPubMed
83.
Praga M, Hernández E, Herrero JC, Morales E, Revilla Y, Díaz-González R, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58:2111–8.CrossRefPubMed
84.
Morales E, Valero MA, Leo NM, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319–27.CrossRefPubMed
85.
Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes. 2005;29:1115–20.CrossRef
86.
Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010;25:1173–83.CrossRefPubMed
87.
Navaneethan S, Yehnert H, Moustarah F, Screiber M, Schauer P, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;10:1565–74.CrossRef
88.
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16:3027–37.CrossRefPubMed
89.
Pascual JM, Rodilla E, Costa JA, Garcia-Escrich M, Gonzalez C, Redon J. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension. 2014;64:1228–34.CrossRefPubMed
90.
Pierine DT, Navarro ME, Minatel IO, Luvizotto RA, Nascimento AF, Ferreira AL, et al. Lycopene supplementation reduces TNF-α via RAGE in the kidney of obese rats. Nutr Diabetes. 2014;4, e142.PubMedCentralCrossRefPubMed
91.
Stacchiotti A, Favero G, Giugno L, Lavazza A, Reiter RJ, Rodella LF, et al. Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin. PLoS One. 2014;9(10):e111141.PubMedCentralCrossRefPubMed
92.
Wang C, Wu M, Arvapalli R, Dai X, Mahmood M, Driscoll H, et al. Acetaminophen attenuates obesity-related renal injury through ER-mediated stress mechanisms. Cell Physiol Biochem. 2014;33:1139–48.CrossRefPubMed
93.
Yoshida S, Ishizawa K, Ayuzawa N, Ueda K, Takeuchi M, Kawarazaki W, et al. Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease. Nephron Exp Nephrol. 2014;126:16–24.CrossRefPubMed
94.
Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, et al. Soluble epoxide hydrolase inhibition and peroxisome proliferator activate receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med (Maywood). 2012;237:1402–12.CrossRef
95.
Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. Am J Physiol Renal Physiol. 2013;305:F613–7.CrossRefPubMed
Metadaten
Titel
The Kidney in Obesity
verfasst von
Josep Redon
Empar Lurbe
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 6/2015
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-015-0555-z

Weitere Artikel der Ausgabe 6/2015

Current Hypertension Reports 6/2015 Zur Ausgabe

Hypertension and the Kidney (RM Carey, Section Editor)

Activation of Mineralocorticoid Receptor in Salt-Sensitive Hypertension

Novel Treatments for Hypertension (T Unger, Section Editor)

Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention

Therapeutic Trials (M Weir, Section Editor)

Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?

Novel Treatments for Hypertension (T Unger, Section Editor)

New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

Dietary Sodium and Cardiovascular Disease

Hypertension and Obesity (E Reisin, Section Editor)

Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise